Starpharma Holdings Limited · ASX:SPL

Starpharma — Shareholder Meeting (November 2004)

22 slides from Starpharma's shareholder meeting presentation, Nov 17, 2004

  1. Slide 1: Chairman's Address, Annual General Meeting

    @ starpharma Chairman’s Address Annual General Meeting of Starpharma Holdings Limited Wednesday 17 November 2004 This is the second AGM at which I've presented the Chairman’s address for Starpharma, a company formed eight years ago to commercialise pharmaceutical applications of dendrimers. I'm prou

  2. Slide 2: Chairman's Address (continued)

    @ starpharma Our network includes ReProtect in the US and the Australian/US NIH-funded consortium of which John will speak. Of course there is no substitute for a good product, and it is with that in mind that | am particularly excited about the progress VivaGel has made and that John will share wit

  3. Slide 3: Chairman's Address (continued)

    @ starpharma a hat. We have to tailor our operation in the realization that Australia will never have access to the sort of resources available in the US and Europe. Another fact of life for Australian biotechnology is that, with so many small cap companies engaged in long-term product development,

  4. Slide 4: Chairman's Address (conclusion)

    @ starpharma It is also worth noting that we are proud to count both their firms, Biotech Capital and QIC, as significant investors in Starpharma. On that upbeat note, | shall now give the floor to our Chief Executive Officer, Dr John Raff, after which we will proceed to the formal business on the a

  5. Slide 5: Presentation by CEO

  6. Slide 6: Starpharma has built an internationally competitive company

    Starpharma has built an internationally concen scum company He Lo SF . Le 7 .. hh eo . Le Le LF Le Lo _ i . Lf hr 7 oe |. = vy Le a ~=——r—“‘—s—s—s—ssSsSs— Le 7 . . LY Le ee |. Lt es oe = i ~~ CC LU i CF lLLhLDLr”r””rrrrrt—t—“(“‘=“OeO™OCOé*#*”#*é*é‘“‘<C‘C‘C‘C‘S ye F oe . oe Z 4 : ie ic a, Mi = ae 2 L

  7. Slide 7: Starpharma pipeline

    y ips up _ 5. WU EE y Boe Goo 7 7 Une IE EES YI ee Ly Dh Ly) ey oo UL LAM EE LEE EE EEE - a. Lo Ae lag olor a TEES a ay y ; Ly ay 8 Le ee TE Ie Ly ey pe 7 — - fe Key - Gi Le TO a Le - i LG Ray Le Oo ae a | oe 7 j LYE By a Le ie a ie a Le p 7 2 ~=—ese CL Le es Lae 0 Le LO Pe af WI ee I I Ve - ee i i

  8. Slide 8: Nanotechnology Outlook

    Nanotechnology Outlook Ye Le oe J Ly a ey, Le 7 Bea i i By LEO OUT ELI FE TEI a a Ly iy Lo Way WOME EO OLE a Z ee a ##3#&3#&32©&” 7 L Lg Maas i IO #373&=v CCC i 2 TG YG Ce Le ~—=—r—O -. Lo OEE LEE EEE EE EEE EES oD Re 7 —r”r—“—iOOCOC—C—rCTCP7TDVDi ‘COC Ge =—OEes Le De RA va 7 A Beg co i no! a I Gear

  9. Slide 9: Dendrimer applications

    endrimer alicia ppc ey . , r y i repre LOU ET Lo Pay —hLrrrrt—“‘“‘“‘“‘“‘“‘ Li Mae hr Co RAY | # }37T7]7FTstaaoFCCi( Te Oe = Wee -. ge |... 7 Oe PE OE Ie LS ena y Oy) Wie, (pa - Lo \¢ i i Bos ae Ce IU ee Li A zi iy) Vane oy oh a RNS EE. YE ULE 7 L =~ CCF Fp a EEE EE LE OE EE I a, 2 DOE ao jy ..§ He a

  10. Slide 10: ee MRE

    ee MRE CC _ ee ee Be EM , Figs _ ae Oe i cy TE Bs CC 2 e Zp ee ee | oe Ae Leh Lo oo 0 j . Sie y a | . ] 3 i le n alent ar 1. Oo Co ie Le Ve iy Lo La _ Ee UE (eo) _ ee Le _ fs mea LE CIEE CEE Lo SS 2. Ay, y es, | incl MUG ye ee yy Le ie OTE Lo Le y ioe — Le Der TERS SOG IER. CCIE ii. _ GA i ae Gn, ae

  11. Slide 11: VivaGel

    As nn - LE LO ae ye Pe Oy, ay, Cl 7 7 Ln Ye - oo. Ge Le LO Le . Lo =—=—r—eseSmsSsh Upc I ete Le oo. 7 LO Re oo 7 EEL . ENE Re Le ig Ly I ETE Lo LMS EMO CEE =|. De . ee ee CC . #3&€©7#7«+»@~CU a US SF . - BI j _ i. ee 7 se Ly hh TEE Co Woe _» VivaGe 2. Yay - Te Ge 5 IE - y LRM he Mees LEE LL , ie . _

  12. Slide 12: VivaGel Phase I clinical trial

    Lo —r—“—~—r——~—s—s—sSsSsSS 7 ~~ Ee | °°}. #}§7&= i €=—ChCeC i _ hh LhLhLDhLUrhLrLLUrLrCUCUrUhUrLU LC .. yy Hey © In January 2004, Starpharma ir Be ae ed 5 Phas ii wd _ : ey CL de ao Ss 4,8 ae a. 5 fi UA y arma oa Le ae i Kae | DC Be y _ > oF Lo Deg ne phesiagn 4 i falere fat . ey l - 7 7 od . Lo ee

  13. Slide 13: Preliminary trial results

    - ~ preliminary resu mye wie Me ‘ ss y — ~=—rr—e Lo Le Ce Wo) _ ~~ ie EL 2S r———O=*SN Wie 7 CD MSE EL ELE Vs LL ME LUG SOI ae Le Te | ‘he stud) Is We ae oe Ce Ty Ve yi TOI a ye y ud Ue ie Lg ey | _ 1 al 7 _.. iy | 2 ob ve | i a iy to epor that frm opic aspect, no subject | | i Seay Tey ay Ree eee Fe

  14. Slide 14: Manufacturing, GMP scale-up

    oe ee LO Ly Ye ey CL Oa Se Ge |, Vie Lees SO MIE: ag LE Te —=—sO CCC Lo y EEE. y Ye ie i LE I) oo EAL Lo .. ey) LEO LE LE Ve . i aaa sie - jet 7 Wee LL ) MIL IE oe, ; | ee ae ie Wy LL oF L EM OIE ETE TE EE Lng, y Ve ee TT, Te i. COC Le facturin a LL a Oe OES le Le UG) Ly yy i a, oe My es Ly Fe ey UN

  15. Slide 15: A$7.5 Million NIH Microbicide Grant

    A$7.5 Million NIH Microbicide Grant - i Te , — ne yy ge > he a, GE) Lye yop RO MEE Lo We |... ss. LO NC | ee Do oy Wg a Ge ah Lie iy, 5 Li Ms ; y Ue Fi AG 4 y Zh oh yy ye i i Ge Wey ee i Ge oe be Lo ape insti 7 Ce ee - / jj ne Cl CO) t f [ [a i g 7 aS SENN — = oS SSS aS Le 1. WE LAM ay ae Yay ~—r—“—

  16. Slide 16: VivaGel's Dendrimer Composition Offers Competitive Advantages

    VivaGel™’s Dendrimer Composition Offers Competitive Advantages WE Li -—rt—“i‘“‘_i™OCCUOC—C—~—CO Hise Ly ey _ LU Le yy oy i ay 7 LD BUH . Lo ee UTE sting E _ | y y i y ee Q ay F Le i eon re 7 Lo oo Ae ae TAG 7 Co L Lo I yo ae - MM yp L Ey Le AG Ly Vi Ws EH IE EET, Ae _ De LE OT EE SL. ae CC Wo - MITE

  17. Slide 17: The HIV Epidemic

  18. Slide 18: Promising Markets For VivaGel

    Promising Markets For Vivagel 1 million infected ROBINSON PROJECTION OF THE WORLD US$600m China High disposable potential Exploding incomes epidemic, 7 government 7 condom usage ; Encamp aoa

  19. Slide 19: Production of high quality products

    ction of high quality Document Control 4 og Licensees Computer Records ee Systems. aig Management Validation’ yy Vendor ) Programs La Assurance Investors | a Collaborators QUALITY | Z HIGHVALUE 7 POLICY | PRODUCTS, F i Clinical Training if : Trials y anagement Regulatory Bodies Partners Materials 7

  20. Slide 20: sip ips

    sip ips Lo J Lee ~=—ers—s—eE tri“ ee 7 CC LAMM ES oe =—r——SFB ee a Ty La Le Le ee Loe Co ey i hr -. —S——r—“_OOCCCUCO—Sh ee a =—r—es—e Le ee ee LTS I en GO oe LG yey @2&=&7©=—eseseme i i... =. EE ese Beye Lo i 2 Le, RAG . _ i GG - ye ay Lo a, ——rt—“‘“—OCOCOC«CwW Bias Gy LE _ ee a iE A Beak | se _. rr

  21. Slide 21: Growth and Value Capture Strategies

    Growth and Value Capture Strategies aerate CO — 7 —Crrt—_O—S ee LLC LLC _ oe oo _ | 2 2~=—he—=#?” é , 7 OD Lo 2 ey [— i CCl . ee .... .... oy with large ma 0 Jc i YR | / Wa) Ly Le |. _ on a Oe Le _— ~~ =——e 7” ~—r—”—“—C—C—C—C—CTCP#'D ss saé$éRsMhékséf. LF rrrtrt“(‘(‘C‘C‘C‘CONCOOCOC#C#C#C#C*éCti‘(‘(y

  22. Slide 22: Internationalising Starpharma's Investor Base

    Internationalising Starpharma’s Investor Base spammers ” , —_ oF ———e To —. —rr—S——S : - hh,r—“—*ti—s—sCOCSsSCs _ har La Oa aa lis' 'Rinte snology Company _ ze i oe iy ‘ i & | oe Giall ayy i , 1OLEC Gy aly i wiht ] aS Le Le _ ] ee u MC ~=—r—=—sSehm—éH—Mi—Prmésé—éFemef _ a ee a y, . #&3&#8€§=—CCs§EsS

Starpharma Holdings — Shareholder Meeting (November 2004) on 6ix